INOSR APPLIED SCIENCES 13(2):147-151, 2025 ISSN: 2705-165X
©INOSR PUBLICATIONS INOSR13.2.000
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRAS/2025/13.2.147151

# The Blood-Brain Barrier in Neurotoxicity: Disruption Mechanisms and Protective Strategies in CNS Drug Design

**Arionget Jemima**

**Department of Pharmacoepidemeology Kampala International University Uganda**
**Email: jemima.arionget@studwc.kiu.ac.ug**

## ABSTRACT

The blood-brain barrier (BBB) serves as a critical gatekeeper, maintaining central nervous system (CNS) homeostasis by tightly regulating the passage of substances between the bloodstream and the brain. However, a growing body of evidence implicates BBB disruption as a central event in various forms of neurotoxicity—whether induced by environmental toxicants, pharmaceuticals, or pathological conditions. This review explores the structural and functional integrity of the BBB, the molecular mechanisms underlying its disruption by neurotoxic agents, and the resulting implications for neuroinflammation, neuronal injury, and cognitive dysfunction. We examine key mediators of BBB breakdown, including oxidative stress, inflammatory cytokines, tight junction protein degradation, and transporter dysregulation. Additionally, we discuss how these insights are reshaping strategies in CNS drug development, with emphasis on designing therapeutics that either preserve BBB integrity or exploit it for targeted delivery without inducing collateral damage. Emerging technologies such as nanoparticle carriers, efflux transporter modulation, and receptor-mediated transcytosis are also reviewed. Understanding the dual role of the BBB, as both a target and barrier in neurotoxicology and pharmacology is essential for advancing neuroprotective therapies and achieving safe, effective CNS drug deliver

**Keywords:** Blood-brain barrier, Neurotoxicity, Tight junctions, CNS drug design, Neuroprotection

## INTRODUCTION

The blood-brain barrier (BBB) is a highly specialized, dynamic interface that regulates the exchange of substances between the circulatory system and the central nervous system (CNS) [1]. Comprised primarily of tightly connected brain endothelial cells, supported by pericytes, astrocytic endfeet, and a basement membrane, the BBB functions as both a physical and biochemical shield [1]. Its role in maintaining CNS homeostasis is critical, it restricts the passage of pathogens, toxins, immune cells, and potentially harmful fluctuations in ion and hormone levels, while selectively allowing essential nutrients and gases to reach neural tissue. Despite these protective functions, the BBB presents a major obstacle in CNS drug development. Its selectivity impedes the delivery of many therapeutic agents, particularly large molecules and biologics [2]. However, the concern extends beyond drug design. Increasing evidence reveals that BBB dysfunction plays a central role in the initiation and progression of neurological diseases [3]. Environmental neurotoxins, inflammatory mediators, and certain pharmacological agents can compromise the BBB's structural and functional integrity [4]. The resulting increased permeability, altered transport activity, and immune cell infiltration contribute to neuroinflammation, neuronal damage, and cognitive impairment. This review examines the mechanisms through which neurotoxic agents disrupt the BBB, including oxidative stress, inflammation, and enzymatic degradation of structural proteins. It also discusses how these disruptions affect neural function and health outcomes. Finally, the review explores contemporary strategies in CNS drug design that aim to preserve or exploit the BBB—offering pathways for safer, more effective treatments of CNS disorders.

### Structure and Function of the Blood-Brain Barrier

The BBB is a multifunctional interface composed of a cellular and acellular matrix that creates a tightly regulated barrier [1]. At its core, the BBB is formed by a monolayer of endothelial cells lining the cerebral microvasculature [5]. These cells are characterized by the presence of tight junctions (TJs), which include transmembrane proteins

such as claudins, occludin, and junctional adhesion molecules (JAMs) [6]. These proteins are linked to cytoplasmic scaffold proteins like zonula occludens-1 (ZO-1), which anchor the junctional complexes to the actin cytoskeleton, maintaining cell polarity and limiting paracellular diffusion [7] The BBB also includes pericytes embedded within the basement membrane. These mural cells regulate endothelial proliferation, vessel stabilization, and permeability [8]. Astrocytes, with their endfeet enwrapping the microvasculature, provide biochemical support and help modulate BBB function through the release of growth factors and neurotransmitters [9]. The basement membrane, composed of extracellular matrix (ECM) proteins like collagen IV, fibronectin, and laminins, offers mechanical stability and contributes to signaling pathways that maintain barrier phenotype [10]. Key functional components of the BBB include transporters and metabolic enzymes. Active transport systems, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (MRPs), expel xenobiotics and restrict CNS drug entry [11]. Facilitated transporters for glucose (GLUT1), amino acids, and vitamins ensure proper nutrient delivery, while metabolic enzymes like monoamine oxidase (MAO) and cytochrome P450s neutralize toxic substances [12]. A fully functional BBB acts as a sentinel that protects the CNS while allowing highly regulated access to systemic inputs. Any disruption of this structure compromises CNS integrity and poses a serious risk to neural homeostasis.

## Mechanisms of BBB Disruption in Neurotoxicity

### *Oxidative Stress*

One of the principal mechanisms by which neurotoxic agents compromise the BBB is through oxidative stress. Exposure to environmental pollutants such as heavy metals (lead, arsenic, mercury), diesel exhaust particles, or tobacco smoke increases the production of reactive oxygen species (ROS) in brain endothelial cells [13]. Chemotherapeutics like cisplatin and doxorubicin also generate ROS as part of their cytotoxic activity [14]. Elevated ROS levels damage lipids, proteins, and DNA within BBB cells. ROS-mediated lipid peroxidation disrupts the lipid bilayer, increasing membrane permeability [15]. Protein oxidation leads to structural compromise of tight junction proteins like claudin-5 and occludin, while mitochondrial dysfunction and endothelial apoptosis further reduce BBB integrity [16]

### *Inflammatory Cytokines*

Peripheral or CNS inflammation triggers the release of cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), which directly modulate BBB properties [17]. These cytokines alter endothelial cell signaling pathways, upregulate adhesion molecules (ICAM-1, VCAM-1), and induce cytoskeletal rearrangements that disassemble tight junctions [18,19]. As a result, vascular permeability increases, facilitating leukocyte infiltration and amplifying local inflammation.

Cytokine-induced activation of NF-κB and STAT3 pathways also downregulates expression of barrier-protective proteins and exacerbates glial activation [20]. This proinflammatory milieu perpetuates a feedback loop of barrier weakening and immune activation.

### *Matrix Metalloproteinases (MMPs)*

Matrix metalloproteinases are zinc-dependent enzymes that degrade ECM components and tight junction proteins [21]. MMP-2 and MMP-9, in particular, are upregulated in response to injury, infection, and exposure to neurotoxicants [22]. Their activity results in basement membrane thinning and increased BBB permeability. For example, MMP-9 cleaves occludin and ZO-1, leading to disruption of the TJ complex [23] Increased MMP activity is observed in multiple pathological states including traumatic brain injury, stroke, multiple sclerosis, and neurodegenerative diseases [24]. Pharmacological inhibition of MMPs has been shown to preserve BBB integrity in preclinical models [25].

### *Transporter and Receptor Dysregulation*

Neurotoxicants can also alter the expression and functionality of BBB transporters and receptors. For instance, exposure to diesel particles or chronic inflammation may reduce P-gp expression, allowing harmful compounds to accumulate in the brain [26]. Alternatively, receptor-mediated endocytosis of cytokines or antibodies may inadvertently serve as entry points for neurotoxic agents [27] Dysregulation of nutrient transporters (e.g., GLUT1) impairs energy supply to neurons, contributing to metabolic stress and neurodegeneration [28]. In sum, transporter and receptor alterations represent an underappreciated but crucial axis of BBB dysfunction.

## Consequences of BBB Breakdown

Disruption of the BBB has profound implications for CNS function. Once the barrier is compromised, circulating neurotoxins, immune cells, and plasma proteins can access the brain parenchyma, initiating a cascade of pathological events. Microglial activation follows, along with astrocytic reactivity and pro-inflammatory cytokine release [29]. These responses contribute to a state of chronic neuroinflammation. Prolonged barrier disruption increases oxidative stress, reduces synaptic density, and impairs long-term potentiation (LTP), a key mechanism of memory formation [30]. Additionally, the loss of BBB integrity impairs clearance of metabolic waste, such as amyloid-β, via the glymphatic system, thereby promoting protein aggregation and neurodegeneration [31] Clinical conditions

associated with BBB disruption include Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy [32]. Even in the absence of a primary neurodegenerative diagnosis, transient barrier leakage, such as that seen in chemotherapy-related cognitive dysfunction, can lead to measurable cognitive deficits and structural brain changes [33] BBB breakdown also affects pharmacokinetics and drug distribution, altering therapeutic efficacy and increasing the risk of neurotoxicity [34]. Thus, maintaining BBB integrity is not only crucial for neuroprotection but also for optimizing CNS pharmacotherapy.

## Protective Strategies in CNS Drug Design

Understanding the vulnerabilities of the BBB has guided the development of protective and targeted strategies in CNS drug design. These strategies aim to either preserve barrier function or enhance drug delivery without compromising its protective role.

### *BBB-Preserving Agents*

A range of pharmacological agents have been identified that protect the BBB from toxic insult. Antioxidants such as N-acetylcysteine and alpha-lipoic acid scavenge free radicals and prevent ROS-induced damage [35]. Anti-inflammatory agents, including corticosteroids and TNF-α inhibitors, can reduce cytokine-mediated BBB disruption [36]. Natural compounds such as curcumin, resveratrol, and quercetin have shown barrier-protective effects through antioxidant, anti-apoptotic, and MMP-inhibitory pathways [37].

### *Nanoparticle-Mediated Delivery*

Nanotechnology provides a versatile platform for bypassing the BBB. Nanoparticles (NPs), liposomes, and polymeric micelles can encapsulate therapeutic agents, protect them from degradation, and facilitate transport across the BBB. Functionalization of NPs with targeting ligands (e.g., transferrin, lactoferrin) enables receptor-mediated transcytosis, allowing drug delivery without compromising barrier integrity [38]. These systems are currently being explored for delivering antineoplastic agents, neuroprotectants, and gene therapies.

### *Receptor-Mediated Transcytosis*

This approach exploits endogenous receptor systems to deliver drugs into the CNS. Molecules such as insulin, transferrin, and low-density lipoprotein (LDL) receptors are expressed on the luminal surface of BBB endothelial cells [39]. Drugs conjugated to ligands of these receptors are internalized and transported across the BBB via vesicular pathways. This strategy ensures targeted delivery while preserving BBB selectivity.

*Efflux Transporter Modulation*

Efflux transporters like P-gp and BCRP limit drug accumulation in the brain [40]. Transient inhibition of these transporters using pharmacological modulators or co-administered adjuvants can improve CNS drug penetration. However, this strategy must be used judiciously to avoid compromising BBB function or allowing neurotoxin influx. Innovations in substrate modification and transporter bypass are ongoing areas of investigation. Collectively, these approaches reflect a growing appreciation of the BBB's complexity and the necessity for precision in CNS drug design. Future therapies will likely combine multiple strategies to achieve optimal delivery while maintaining long-term barrier integrity.

## Future Directions and Challenges

The dual role of the BBB in protecting and restricting the brain presents ongoing challenges in drug development. Future research should focus on integrating BBB permeability assays into early drug screening, developing biomarkers for barrier integrity, and tailoring delivery platforms to patient-specific pathologies. Moreover, understanding individual variability in BBB function due to age, genetics, or comorbid conditions will be critical for advancing personalized neurotherapeutics.

## CONCLUSION

The blood-brain barrier is central to both neuroprotection and neuropharmacology. Disruption of its integrity is a key event in many neurotoxic pathways, contributing to neuroinflammation and cognitive decline. At the same time, the BBB remains a significant obstacle in the delivery of CNS therapeutics. Advances in our understanding of BBB biology and pathophysiology offer promising avenues for the development of protective and penetrative strategies in CNS drug design, ultimately enabling safer and more effective treatment of neurological disorders.

## REFERENCES

1. Dotiwala AK, McCausland C, Samra NS. Anatomy, head and neck: blood brain barrier. StatPearls-NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519556/
2. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: Structure, regulation and drug delivery. Signal Transduction and Targeted Therapy. 2023;8(1). doi:10.1038/s41392-023-01481-w
3. Patabendige A, Janigro D. The role of the blood–brain barrier during neurological disease and infection. Biochemical Society Transactions. 2023;51(2):613–26. doi:10.1042/BST20220830
4. Chen T, Dai Y, Hu C, Lin Z, Wang S, Yang J, et al. Cellular and molecular mechanisms of the blood–brain barrier dysfunction in neurodegenerative diseases. Fluids and Barriers of the CNS. 2024;21(1). doi:10.1186/s12987-024-00557-1

5. Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids and Barriers of the CNS. 2020;17(1). doi:10.1186/s12987-020-00230-3
6. Wibbe N, Ebnet K. Cell adhesion at the tight junctions: new aspects and new functions. Cells. 2023;12(23):2701. doi:10.3390/cells12232701
7. Bron AJ, Argüeso P, Irkec M, Bright FV. Clinical staining of the ocular surface: Mechanisms and interpretations. Progress in Retinal and Eye Research. 2014;44:36–61. doi:10.1016/j.preteyeres.2014.10.001
8. Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nature Neuroscience. 2016;19(6):771–83. doi:10.1038/nn.4288
9. Cabezas R, Ávila M, Gonzalez J, El-Bachá RS, Báez E, García-Segura LM, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Frontiers in Cellular Neuroscience. 2014;8. doi:10.3389/fncel.2014.00211
10. Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood–brain barrier formation and stroke. Developmental Neurobiology. 2011;71(11):1018–39. doi:10.1002/dneu.20954
11. Juvale IIA, Hamid AAA, Halim KBA, Has ATC. P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon. 2022;8(6):e09777. doi:10.1016/j.heliyon.2022.e09777
12. Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophysical Reviews. 2016;8(1):5–9. doi:10.1007/s12551-015-0186-2
13. Alum EU, Essien EB, Abbey EW. Heavy Metals Content of Food Crops Grown in Oil Exploration Areas of Rivers State. *International Journal of Science and Nature*, **5** (3):486-493. (2014).
14. Yang H, Villani RM, Wang H, Simpson MJ, Roberts MS, Tang M, et al. The role of cellular reactive oxygen species in cancer chemotherapy. Journal of Experimental & Clinical Cancer Research. 2018;37(1). doi:10.1186/s13046-018-0909-x
15. Afzal S, Manap ASA, Attiq A, Albokhadaim I, Kandeel M, Alhojaily SM. From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1269581
16. Kim S, Jung UJ, Kim SR. Role of oxidative stress in blood–brain barrier disruption and neurodegenerative diseases. Antioxidants. 2024;13(12):1462. doi:10.3390/antiox13121462
17. Versele R, Sevin E, Gosselet F, Fenart L, Candela P. TNF-α and IL-1β modulate blood-brain barrier permeability and decrease amyloid-β peptide efflux in a human blood-brain barrier model. International Journal of Molecular Sciences. 2022;23(18):10235. doi:10.3390/ijms231810235
18. Bui TM, Wiesolek HL, Sumagin R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. Journal of Leukocyte Biology. 2020;108(3):787–99. doi:10.1002/jlb.2MR0220-549R
19. Van Wetering S, Van Den Berk N, Van Buul JD, Mul FPJ, Lommerse I, Mous R, et al. VCAM-1-mediated Rac signaling controls endothelial cell–cell contacts and leukocyte transmigration. AJP Cell Physiology. 2003;285(2):C343–52. doi:10.1152/ajpcell.00048.2003
20. Ageeva T, Rizvanov A, Mukhamedshina Y. NF-κB and JAK/STAT signaling pathways as crucial regulators of neuroinflammation and astrocyte modulation in spinal cord injury. Cells. 2024;13(7):581. doi:10.3390/cells13070581
21. Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1-73. doi: 10.1016/bs.pmbts.2017.02.005. Epub 2017 Mar 22. PMID: 28413025; PMCID: PMC5430303.
22. Cabral-Pacheco GA, Garza-Veloz I, La Rosa CCD, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. International Journal of Molecular Sciences. 2020;21(24):9739. doi:10.3390/ijms21249739
23. Bauer AT, Bürgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. Journal of Cerebral Blood Flow & Metabolism. 2009;30(4):837–48. doi:10.1038/jcbfm.2009.248
24. Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C, et al. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. International Journal of Molecular Sciences. 2021;22(3):1413. doi:10.3390/ijms22031413
25. Kawa H, Ahmed Z, Majid A, Chen R. Inhibition of matrix metalloproteinases to reduce blood brain barrier disruption and haemorrhagic transformation in ischaemic stroke: Go broad or go narrow? Neuropharmacology. 2024;110192. doi:10.1016/j.neuropharm.2024.110192

26. Aquino GV, Dabi A, Odom GJ, Lavado R, Nunn K, Thomas K, et al. Evaluating the effect of acute diesel exhaust particle exposure on P-glycoprotein efflux transporter in the blood–brain barrier co-cultured with microglia. Current Research in Toxicology. 2023;4:100107. doi:10.1016/j.crtox.2023.100107
27. Popoff MR, Poulain B. Bacterial toxins and the nervous system: Neurotoxins and multipotential toxins interacting with neuronal cells. Toxins. 2010;2(4):683–737. doi:10.3390/toxins2040683
28. Han R, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases—New mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. International Journal of Molecular Sciences. 2021;22(11):5887. doi:10.3390/ijms22115887
29. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Research Bulletin. 2011;87(1):10–20. doi:10.1016/j.brainresbull.2011.10.004
30. Navakkode S, Kennedy BK. Neural ageing and synaptic plasticity: Prioritizing brain health in healthy longevity. Frontiers in Aging Neuroscience. 2024;16. doi:10.3389/fnagi.2024.1428244
31. Sweeney MD, Sagare AP, Zlokovic BV. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018;14(3):133–50. doi:10.1038/nrneurol.2017.188
32. Archie SR, Shoyaib AA, Cucullo L. Blood–brain barrier dysfunction in CNS disorders and putative therapeutic targets: An overview. Pharmaceutics. 2021;13(11):1779. doi:10.3390/pharmaceutics13111779
33. Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al. Mechanisms of chemotherapy-induced neurotoxicity. Frontiers in Pharmacology. 2022;13. doi:10.3389/fphar.2022.750507
34. Pimentel E, Sivalingam K, Doke M, Samikkannu T. Effects of drugs of abuse on the blood–brain barrier: A brief overview. Frontiers in Neuroscience. 2020;14. doi:10.3389/fnins.2020.00513
35. Superti F, Russo R. Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants. 2024;13(10):1228. doi:10.3390/antiox13101228
36. Mallick R, Basak S, Chowdhury P, Bhowmik P, Das RK, Banerjee A, et al. Targeting cytokine-mediated inflammation in brain disorders: Developing new treatment strategies. Pharmaceuticals. 2025;18(1):104. doi:10.3390/ph18010104
37. Warias P, Plewa P, Poniewierska-Baran A. Resveratrol, piceatannol, curcumin, and quercetin as therapeutic targets in gastric cancer—Mechanisms and clinical implications for natural products. Molecules. 2024;30(1):3. doi:10.3390/molecules30010003
38. Alum EU, Nwuruku OA, Ugwu OPC, Uti DE, Alum BN, Edwin N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
39. Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Frontiers in Neuroscience. 2019;12. doi:10.3389/fnins.2018.01019
40. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends in Pharmacological Sciences. 2010;31(6):246–54. doi:10.1016/j.tips.2010.03.003


**CITE AS: Arionget Jemima (2025). The Blood-Brain Barrier in Neurotoxicity: Disruption Mechanisms and Protective Strategies in CNS Drug Design. INOSR APPLIED SCIENCES 13(2):147-151. https://doi.org/10.59298/INOSRAS/2025/13.2.147151**